The stock of Abbott Laboratories (NYSE:ABT) increased by increased by $1.67 on Friday to finish at $126.72, up 1.34 percent. The last five days have seen an average of 6,056,800 shares of common stock traded. 22 times new highs were reached in the current year, with a gain of $17.23. The average number of shares traded over the last 20 days was 5,541,455, while the average volume over the last 50 days totaled 4,851,224.
ABT stock appreciated 1.13% since last month. On 10/06/21, the company’s shares reached a one-month low of $114.40. The stock touched a high of $129.70 on 09/13/21, after rallying from a low of $103.13 in 52 weeks. The price of ABT stock has risen by 15.74% or $17.23 this year, reaching a new high 22 times. Still, the stock price is down -2.30% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 47 days since Abbott Laboratories (ABT) last reported insider trading activity on Sep 08. On Sep 08, SENIOR VICE PRESIDENT PEDERSON MICHAEL J sold 23,008 shares at $129.05 each. This transaction resulted in the insider making $2,969,173. On Sep 03, WOODGRIFT RANDEL WILLIAM sold 6,350 shares at a price of US$129.00. After the transaction, the insider now owns 43,743 shares. EXECUTIVE VICE PRESIDENT Wainer Andrea F had earlier sold 9,500 shares on Sep 02 for $127.50 a share. The transaction was completed for $1,211,250.
Abbott Laboratories (ABT) has a trailing price-to-earnings (P/E) ratio of 31.23. This level actually compares favorably with the industry at large, as the PE for the Medical Devices industry stands at about 43.29. Further, its PE also compares favorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Abbott Laboratories has varied between 254.16 and 28.67 in the last five years. Beta for the stock is 0.66. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 5.24, the price-to-book (PB) ratio of 6.67, and the price-to-cash flow ratio of 45.36.
Abbott Laboratories’s dividend is $1.80 per share per year. With a dividend yield of 1.42%, ABT has a payout ratio of 47.50%. Company paid $0.45 per share in dividends, remained unchanged from $0.45 last year. A $0.09 dividend increase was reported on Friday December 11 2020, making it the 49 consecutive year the dividend has increased. Over the last three years, dividends have increased by 35.85%.
For the three months ended June 29, Abbott Laboratories’s quick ratio was 1.40, while its current ratio was 1.80, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.52, and the total debt to equity ratio is 0.55. As far as profitability goes, gross margin for the trailing twelve months is 56.90% percent. Abbott Laboratories’s EBITDA margin for the year ended June 29 was 24.90%, whereas its operating margin stood at 16.00% for the same period. Based on annual data, it had gross profit of $19.61 billion and revenue of $34.61 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ABT’s return on assets (ROA) during the last 12 months has been 8.00%. There was a 9.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 17.40%. ROE has averaged 3.96 in the past year for the broader industry.
According to Abbott Laboratories’s quarterly financial report for the quarter that ended June 29, it had $17.55 billion in total debt versus $286.0 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $10.22 billion, while revenues rose by 28.32% to $10.46 billion. It was predicted that Abbott Laboratories’s quarterly earnings would be $1.17, but it ended up being $1.02, beating the consensus by 14.70%. EBITDA was $2.27 billion for the quarter. At the end of Abbott Laboratories’s most recent quarter ended June 29, its liabilities totaled 39.24 billion, while its total debt was $18.44 billion. Equity owned by shareholders amounts to $1.77 billion.
Here’s a quick look at Abbott Laboratories’s (ABT) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 77.23%, suggesting the stock is Overbought, with a 17.21% historical volatility rate.
The stochastic %K and %D were 93.27% and 82.49% respectively, while the average true range (ATR) was 2.32. Based on the 14-day stochastic reading of 99.04%, the RSI (14) reading is 67.76%. On the 9-day MACD Oscillator, the stock is at 4.96, and the 14-day reading is at 6.01.
In its analyst report released on October 14, 2021, Redburn began covering Abbott Laboratories (NYSE: ABT). The stock was rated as a Neutral by the brokerage firm. Analysts have assigned Abbott Laboratories (ABT) an Overweight rating. ABT is a stock that is recommended for selling by 1 brokerage firm, while 4 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 4 rates it overweight and 15 others recommend it as a buy.
What is ABT’s price target for the next 12 months?
The current consensus forecast for the stock is between $109.00 and $146.00, with a median target price of $138.00. In analyzing these forecasts, the average price target given by analysts for Abbott Laboratories (ABT) is $136.10.